Skip to main content

Should an institution that has commercial rights in a new drug or device be allowed to evaluate the technology?

Publication ,  Journal Article
McKinney, R; Korn, D
Published in: PLoS Med
January 2005

In the United States, the passage of the Bayh-Dole Act in 1980 encouraged universities to license inventions for commercial development. Although this financial incentive can stimulate academic researchers to discover new drugs and devices, there is concern that the possibility of monetary reward could distort investigators' objectivity.

Duke Scholars

Published In

PLoS Med

DOI

EISSN

1549-1676

Publication Date

January 2005

Volume

2

Issue

1

Start / End Page

e9

Location

United States

Related Subject Headings

  • United States
  • Public Policy
  • Licensure
  • General & Internal Medicine
  • Equipment and Supplies
  • Conflict of Interest
  • Clinical Trials as Topic
  • Biomedical Research
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
McKinney, R., & Korn, D. (2005). Should an institution that has commercial rights in a new drug or device be allowed to evaluate the technology? PLoS Med, 2(1), e9. https://doi.org/10.1371/journal.pmed.0020009
McKinney, Ross, and David Korn. “Should an institution that has commercial rights in a new drug or device be allowed to evaluate the technology?PLoS Med 2, no. 1 (January 2005): e9. https://doi.org/10.1371/journal.pmed.0020009.
McKinney, Ross, and David Korn. “Should an institution that has commercial rights in a new drug or device be allowed to evaluate the technology?PLoS Med, vol. 2, no. 1, Jan. 2005, p. e9. Pubmed, doi:10.1371/journal.pmed.0020009.

Published In

PLoS Med

DOI

EISSN

1549-1676

Publication Date

January 2005

Volume

2

Issue

1

Start / End Page

e9

Location

United States

Related Subject Headings

  • United States
  • Public Policy
  • Licensure
  • General & Internal Medicine
  • Equipment and Supplies
  • Conflict of Interest
  • Clinical Trials as Topic
  • Biomedical Research
  • 42 Health sciences
  • 32 Biomedical and clinical sciences